<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196026</url>
  </required_header>
  <id_info>
    <org_study_id>114451</org_study_id>
    <nct_id>NCT01196026</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine Fluarix™ in Children Previously Vaccinated With GSK Biologicals' H1N1 Vaccine Pandemrix™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is designed to assess the immunogenicity, reactogenicity and safety following
      vaccination with GSK Biologicals' Fluarix vaccine in children who have previously been
      vaccinated with two doses of Pandemrix at the age of 6 months-9 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine</measure>
    <time_frame>Day 0 and 28</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seropositive for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</measure>
    <time_frame>Day 0-28</time_frame>
    <description>Seropositivity was defined as antibody titers greater than or equal to 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroprotected for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</measure>
    <time_frame>Day 0-28</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>A seroconverted subject was defined as a subject that had either a prevaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers Against All Fluarix Vaccine Strains</measure>
    <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
    <description>Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were Flu A/CAL/7/09 H1N1 , FluB/Bri/60/08 Victoria, and Flu A/Vic/210/09 H3N2, further in this summary denoted as H1N1, Victoria and H3N2 strains, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Day 0 and Month 6</time_frame>
    <description>Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for HI Antibodies Against All Fluarix Vaccine Strains</measure>
    <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
    <description>Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Day 0 and Month 6</time_frame>
    <description>Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for HI Antibodies Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Month 6</time_frame>
    <description>A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for HI Antibodies Against All Fluarix Vaccine Strains</measure>
    <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Day 0 and Month 6</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Geometric Increase (MGI) in HI Antibody Titers Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Month 6</time_frame>
    <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Month 6) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neutralising Antibody Titers Against All Fluarix Vaccine Strains</measure>
    <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
    <description>Antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neutralising Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Day 0 and Month 6</time_frame>
    <description>Antibody titers were expressed as GMTs.] Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains</measure>
    <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
    <description>Seropositivity was defined as antibody titers greater than or equal to 1:28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Day 0 and Month 6</time_frame>
    <description>Seropositivity was defined as antibody titers greater than or equal to 1:28. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains in Subjects Receiving Fluarix</measure>
    <time_frame>Day 28</time_frame>
    <description>Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</measure>
    <time_frame>Month 6</time_frame>
    <description>Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7 days (Day 0 - 6) after vaccination</time_frame>
    <description>Solicited local symptoms assessed include: pain, redness and swelling. Any is any symptom regardless of intensity. Grade 3 was defined as a symptom that prevented normal activity.above 50 millimeter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Solicited Local Symptom</measure>
    <time_frame>During the 7 days (Days 0 - 6) after vaccination</time_frame>
    <description>Duration was expressed as median number of days the symptom persisted. Solicited local symptoms assessed include: pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Less Than 6 Years Reporting Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7 days (Days 0-6) after vaccination</time_frame>
    <description>Solicited general symptoms assessed include diarrhoea, drowsiness, irritability, loss of appetite and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 loss of appetite was not eating at all; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Solicited General Symptom Experienced by Subjects Less Than 6 Years Old</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include diarrhoea, drowsiness, irritability, loss of appetite and fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Above 6 Years Reported Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Solicited general symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering, sweating and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Solicited General Symptom Experienced by Subjects Above 6 Years Old</measure>
    <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
    <description>Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During a 28 day follow-up period (Day 0-27) after vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as any symptom regardless of intensity or relationship to vaccination. Grade 3 was a symptom preventing normal everyday activity. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically-Attended Events (MAEs), Adverse Events of Specific Interest (AESIs)/ Potential Immune Mediated Diseases (pIMDs) and Adverse Events (AEs) of Special Interest</measure>
    <time_frame>During the entire study period (up to Month 6)</time_frame>
    <description>MAEs: subject received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.
AESIs/pIMD: includes both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Adverse events of special interest include both convulsion and anaphylaxis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Fluarix 6-11 months Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix 12-35 months Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix 3-9 years Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix Junior 6-11 months Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix Junior 12-35 months Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix Junior 3-9 years Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™</intervention_name>
    <description>One or two intramuscular injections</description>
    <arm_group_label>Fluarix 6-11 months Group</arm_group_label>
    <arm_group_label>Fluarix 12-35 months Group</arm_group_label>
    <arm_group_label>Fluarix 3-9 years Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix™ Junior</intervention_name>
    <description>Two intramuscular injections</description>
    <arm_group_label>Havrix Junior 12-35 months Group</arm_group_label>
    <arm_group_label>Havrix Junior 6-11 months Group</arm_group_label>
    <arm_group_label>Havrix Junior 3-9 years Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects having previously been immunized with two 0.25 mL doses of Pandemrix, given
             at least 21 days apart, at the age of 6 months to 9 years inclusive at the time of
             first vaccination.

          -  Subjects having received the last dose of Pandemrix at least six months prior to study
             enrolment.

          -  Subjects who the investigator believes that parent(s)/Legally Acceptable
             Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subjects.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Parent/LAR with access to a consistent means of telephone contact, land line or
             mobile, but NOT a pay phone or other multiple-user device.

        Exclusion Criteria:

          -  Active participation in other clinical trials.

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of the study vaccine or planned use during the
             study period.

          -  Planned administration of any vaccine 30 days prior and 30 days after any study
             vaccine administration.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             three months prior to enrolment in this study or planned administration during the
             study period.

          -  Acute disease and/or fever at the time of enrolment.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by medical history and physical examination.

          -  Administration of immunoglobulins and/or any blood products within the three months
             prior to the enrolment in this study, or planned use during the study.

          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of
             anaphylactic-type reaction to any constituent of influenza vaccines; or a history of
             severe adverse reaction to a previous influenza vaccine.

          -  History of seizures or progressive neurological disease.

          -  Subjects having received an H1N1v pandemic vaccine other than Pandemrix or having
             received the 2010/2011 seasonal influenza vaccine.

          -  Child in care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 EN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skellefteå</city>
        <zip>SE-931 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-702 11</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <results_first_submitted>March 12, 2012</results_first_submitted>
  <results_first_submitted_qc>May 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2012</results_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>H1N1</keyword>
  <keyword>Fluarix</keyword>
  <keyword>Pandemrix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114451</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114451</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114451</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114451</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114451</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114451</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Primed subjects =subjects who had been previously vaccinated with a seasonal influenza vaccine whereas unprimed subjects had not.
children ≥ 9 years + primed children &lt; 9 years=1 dose of Fluarix
unprimed children &lt; 9 years=2 doses of Fluarix. To complete the vaccination schedule, a 2nd dose of Havrix vaccine was given outside the study setting</recruitment_details>
      <pre_assignment_details>162 subjects were enrolled in the study but only 154 subjects were vaccinated. The remaining 8 subjects gave their consent withdrawal and were not included in the study.Enrollment was stratified according to the age at first Pandemrix vaccination: 6-11 months, 12-35 months, 3-9 years. Also, subjects were grouped from 3-5 and from 6-9 years.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluarix 6-11 Months Group</title>
          <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix 12-35 Months Group</title>
          <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="P3">
          <title>Fluarix 3-9 Years Group</title>
          <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="P4">
          <title>Havrix Junior 6-11 Months Group</title>
          <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
        <group group_id="P5">
          <title>Havrix Junior 12-35 Months Group</title>
          <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
        <group group_id="P6">
          <title>Havrix Junior 3-9 Years Group</title>
          <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed at Day 28</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluarix 6-11 Months Group</title>
          <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="B2">
          <title>Fluarix 12-35 Months Group</title>
          <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="B3">
          <title>Fluarix 3-9 Years Group</title>
          <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="B4">
          <title>Havrix Junior 6-11 Months Group</title>
          <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
        <group group_id="B5">
          <title>Havrix Junior 12-35 Months Group</title>
          <description>Subjects aged 12-35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine.</description>
        </group>
        <group group_id="B6">
          <title>Havrix Junior 3-9 Years Group</title>
          <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.00"/>
                    <measurement group_id="B2" value="2.3" spread="0.52"/>
                    <measurement group_id="B3" value="6.4" spread="1.99"/>
                    <measurement group_id="B4" value="1.0" spread="0.00"/>
                    <measurement group_id="B5" value="2.4" spread="0.58"/>
                    <measurement group_id="B6" value="7.5" spread="1.53"/>
                    <measurement group_id="B7" value="3.58" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs).</description>
        <time_frame>Day 0 and 28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs).</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="120.7" lower_limit="100.8" upper_limit="144.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="1079.3" lower_limit="915.8" upper_limit="1272.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seropositive for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
        <description>Seropositivity was defined as antibody titers greater than or equal to 1:10.</description>
        <time_frame>Day 0-28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
          <description>Seropositivity was defined as antibody titers greater than or equal to 1:10.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroprotected for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
        <time_frame>Day 0-28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
        <description>A seroconverted subject was defined as a subject that had either a prevaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for HI Antibodies Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
          <description>A seroconverted subject was defined as a subject that had either a prevaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
        <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in All Subjects Receiving Fluarix Vaccine</title>
          <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. The data presented here are only for the Fluarix All Ages Group. Similar data for other groups will be presented as Secondary Outcome Measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="8.9" lower_limit="7.1" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers Against All Fluarix Vaccine Strains</title>
        <description>Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were Flu A/CAL/7/09 H1N1 , FluB/Bri/60/08 Victoria, and Flu A/Vic/210/09 H3N2, further in this summary denoted as H1N1, Victoria and H3N2 strains, respectively.</description>
        <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers Against All Fluarix Vaccine Strains</title>
          <description>Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were Flu A/CAL/7/09 H1N1 , FluB/Bri/60/08 Victoria, and Flu A/Vic/210/09 H3N2, further in this summary denoted as H1N1, Victoria and H3N2 strains, respectively.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available.</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.6" lower_limit="79.3" upper_limit="393.4"/>
                    <measurement group_id="O2" value="124.9" lower_limit="97.1" upper_limit="160.5"/>
                    <measurement group_id="O3" value="102.0" lower_limit="77.2" upper_limit="134.9"/>
                    <measurement group_id="O4" value="171.4" lower_limit="118.9" upper_limit="247.2"/>
                    <measurement group_id="O5" value="186.5" lower_limit="148.8" upper_limit="233.8"/>
                    <measurement group_id="O6" value="105.3" lower_limit="75.4" upper_limit="147.0"/>
                    <measurement group_id="O7" value="120.7" lower_limit="100.8" upper_limit="144.4"/>
                    <measurement group_id="O8" value="154.4" lower_limit="129.8" upper_limit="183.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1810.2" lower_limit="775.2" upper_limit="4226.8"/>
                    <measurement group_id="O2" value="1345.0" lower_limit="1141.9" upper_limit="1584.1"/>
                    <measurement group_id="O3" value="659.7" lower_limit="524.1" upper_limit="830.3"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="1079.3" lower_limit="915.8" upper_limit="1272.0"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="3.7" upper_limit="71.9"/>
                    <measurement group_id="O2" value="15.1" lower_limit="10.6" upper_limit="21.5"/>
                    <measurement group_id="O3" value="21.9" lower_limit="14.0" upper_limit="34.1"/>
                    <measurement group_id="O4" value="13.6" lower_limit="7.6" upper_limit="24.6"/>
                    <measurement group_id="O5" value="19.1" lower_limit="14.4" upper_limit="25.4"/>
                    <measurement group_id="O6" value="19.1" lower_limit="12.3" upper_limit="29.6"/>
                    <measurement group_id="O7" value="17.4" lower_limit="13.2" upper_limit="22.8"/>
                    <measurement group_id="O8" value="18.3" lower_limit="14.8" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.8" lower_limit="28.1" upper_limit="1111.2"/>
                    <measurement group_id="O2" value="142.2" lower_limit="93.5" upper_limit="216.2"/>
                    <measurement group_id="O3" value="188.8" lower_limit="103.7" upper_limit="343.8"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="160.9" lower_limit="115.0" upper_limit="225.2"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="21.2" lower_limit="13.7" upper_limit="32.8"/>
                    <measurement group_id="O3" value="31.0" lower_limit="19.0" upper_limit="50.5"/>
                    <measurement group_id="O4" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="8.9" lower_limit="6.4" upper_limit="12.4"/>
                    <measurement group_id="O6" value="26.7" lower_limit="16.6" upper_limit="42.9"/>
                    <measurement group_id="O7" value="20.8" lower_limit="15.2" upper_limit="28.3"/>
                    <measurement group_id="O8" value="11.7" lower_limit="8.9" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" lower_limit="35.9" upper_limit="217.6"/>
                    <measurement group_id="O2" value="448.3" lower_limit="265.9" upper_limit="755.8"/>
                    <measurement group_id="O3" value="518.6" lower_limit="304.1" upper_limit="884.3"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="396.3" lower_limit="276.3" upper_limit="568.5"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Day 0 and Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>Antibody titers were expressed as GMTs. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.6" lower_limit="81.1" upper_limit="501.1"/>
                    <measurement group_id="O2" value="126.4" lower_limit="93.2" upper_limit="171.4"/>
                    <measurement group_id="O3" value="96.9" lower_limit="73.9" upper_limit="126.9"/>
                    <measurement group_id="O4" value="172.8" lower_limit="113.9" upper_limit="262.1"/>
                    <measurement group_id="O5" value="195.6" lower_limit="155.1" upper_limit="246.6"/>
                    <measurement group_id="O6" value="100.3" lower_limit="71.8" upper_limit="140.1"/>
                    <measurement group_id="O7" value="119.7" lower_limit="97.9" upper_limit="146.3"/>
                    <measurement group_id="O8" value="154.6" lower_limit="128.8" upper_limit="185.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Month 6 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1437.0" lower_limit="595.7" upper_limit="3466.6"/>
                    <measurement group_id="O2" value="565.5" lower_limit="458.1" upper_limit="698.2"/>
                    <measurement group_id="O3" value="335.5" lower_limit="253.1" upper_limit="444.7"/>
                    <measurement group_id="O4" value="93.4" lower_limit="48.6" upper_limit="179.5"/>
                    <measurement group_id="O5" value="172.0" lower_limit="127.9" upper_limit="231.4"/>
                    <measurement group_id="O6" value="74.3" lower_limit="55.4" upper_limit="99.6"/>
                    <measurement group_id="O7" value="509.0" lower_limit="416.9" upper_limit="621.5"/>
                    <measurement group_id="O8" value="120.7" lower_limit="97.2" upper_limit="149.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="2.9" upper_limit="110.0"/>
                    <measurement group_id="O2" value="16.2" lower_limit="10.6" upper_limit="24.6"/>
                    <measurement group_id="O3" value="21.6" lower_limit="13.6" upper_limit="34.5"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="18.3" lower_limit="13.5" upper_limit="24.8"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.0" lower_limit="115.6" upper_limit="788.8"/>
                    <measurement group_id="O2" value="148.4" lower_limit="97.9" upper_limit="225.1"/>
                    <measurement group_id="O3" value="134.5" lower_limit="82.2" upper_limit="220.1"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="154.1" lower_limit="115.3" upper_limit="205.9"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="20.3" lower_limit="12.4" upper_limit="33.0"/>
                    <measurement group_id="O3" value="29.7" lower_limit="17.9" upper_limit="49.2"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="20.3" lower_limit="14.5" upper_limit="28.2"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.0" lower_limit="70.1" upper_limit="230.0"/>
                    <measurement group_id="O2" value="160.0" lower_limit="119.1" upper_limit="214.8"/>
                    <measurement group_id="O3" value="252.7" lower_limit="186.3" upper_limit="342.8"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="186.8" lower_limit="152.9" upper_limit="228.2"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for HI Antibodies Against All Fluarix Vaccine Strains</title>
        <description>Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
        <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for HI Antibodies Against All Fluarix Vaccine Strains</title>
          <description>Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="65"/>
                    <measurement group_id="O8" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="65"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="65"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="41"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="65"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Day 0 and Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>Seropositivity was defined as antibody titers greater than or equal to 1:10. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Month 6 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="43"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for HI Antibodies Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine</title>
        <description>A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for HI Antibodies Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine</title>
          <description>A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>A seroconverted subject was defined as a subject that had either a pre-vaccination (Day 0) titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1(N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="46"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for HI Antibodies Against All Fluarix Vaccine Strains</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
        <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for HI Antibodies Against All Fluarix Vaccine Strains</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="63"/>
                    <measurement group_id="O8" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="65"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="63"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O5" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O6" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                    <measurement group_id="O7" value="65"/>
                    <measurement group_id="O8" value="NA">Data not planned to be collected at Day 28, but rather at Month 6.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Day 0 and Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for HI Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="54"/>
                    <measurement group_id="O8" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Month 6 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="52"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Geometric Increase (MGI) in HI Antibody Titers Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine</title>
        <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Geometric Increase (MGI) in HI Antibody Titers Against All Fluarix Vaccine Strains in All Subjects Receiving Fluarix Vaccine</title>
          <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 28) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.0" upper_limit="34.8"/>
                    <measurement group_id="O2" value="10.8" lower_limit="7.9" upper_limit="14.7"/>
                    <measurement group_id="O3" value="6.5" lower_limit="4.7" upper_limit="8.8"/>
                    <measurement group_id="O7" value="8.9" lower_limit="7.1" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="5.9" upper_limit="19.6"/>
                    <measurement group_id="O2" value="9.4" lower_limit="6.8" upper_limit="12.9"/>
                    <measurement group_id="O3" value="8.6" lower_limit="5.5" upper_limit="13.6"/>
                    <measurement group_id="O7" value="9.3" lower_limit="7.3" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="7.2" upper_limit="43.5"/>
                    <measurement group_id="O2" value="21.1" lower_limit="16.3" upper_limit="27.4"/>
                    <measurement group_id="O3" value="16.7" lower_limit="11.4" upper_limit="24.6"/>
                    <measurement group_id="O7" value="19.1" lower_limit="15.6" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Month 6) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Geometric Increase (MGI) in HI Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>MGI is defined as the geometric mean of the within-subject ratios of the post-vaccination (Month 6) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="2.0" upper_limit="25.5"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.3" upper_limit="6.0"/>
                    <measurement group_id="O3" value="3.5" lower_limit="2.6" upper_limit="4.7"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.4" upper_limit="0.8"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                    <measurement group_id="O6" value="0.7" lower_limit="0.7" upper_limit="0.8"/>
                    <measurement group_id="O7" value="4.3" lower_limit="3.4" upper_limit="5.3"/>
                    <measurement group_id="O8" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="3.1" upper_limit="93.9"/>
                    <measurement group_id="O2" value="9.2" lower_limit="5.9" upper_limit="14.2"/>
                    <measurement group_id="O3" value="6.2" lower_limit="3.8" upper_limit="10.2"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="8.4" lower_limit="6.1" upper_limit="11.6"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" lower_limit="14.0" upper_limit="46.0"/>
                    <measurement group_id="O2" value="7.9" lower_limit="5.5" upper_limit="11.4"/>
                    <measurement group_id="O3" value="8.5" lower_limit="5.9" upper_limit="12.3"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="9.2" lower_limit="7.2" upper_limit="11.8"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Neutralising Antibody Titers Against All Fluarix Vaccine Strains</title>
        <description>Antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
        <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Neutralising Antibody Titers Against All Fluarix Vaccine Strains</title>
          <description>Antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359.1" lower_limit="159.7" upper_limit="807.4"/>
                    <measurement group_id="O2" value="235.4" lower_limit="180.5" upper_limit="307.0"/>
                    <measurement group_id="O3" value="237.6" lower_limit="154.7" upper_limit="364.8"/>
                    <measurement group_id="O7" value="247.3" lower_limit="199.6" upper_limit="306.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Day 28 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5706.2" lower_limit="3382.6" upper_limit="9626.0"/>
                    <measurement group_id="O2" value="5860.4" lower_limit="5072.5" upper_limit="6770.7"/>
                    <measurement group_id="O3" value="2052.3" lower_limit="1395.1" upper_limit="3019.0"/>
                    <measurement group_id="O7" value="4007.7" lower_limit="3274.8" upper_limit="4904.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0 (N=7;35;23;0;0;0;65;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="8.3" upper_limit="49.2"/>
                    <measurement group_id="O2" value="19.1" lower_limit="13.9" upper_limit="26.2"/>
                    <measurement group_id="O3" value="25.4" lower_limit="16.6" upper_limit="38.9"/>
                    <measurement group_id="O7" value="21.3" lower_limit="16.8" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 28 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" lower_limit="6.9" upper_limit="349.5"/>
                    <measurement group_id="O2" value="42.3" lower_limit="20.9" upper_limit="85.5"/>
                    <measurement group_id="O3" value="80.8" lower_limit="34.8" upper_limit="187.9"/>
                    <measurement group_id="O7" value="54.3" lower_limit="33.0" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0 (N=7;35;23;0;0;0;65;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="13.5" upper_limit="66.9"/>
                    <measurement group_id="O2" value="84.9" lower_limit="53.7" upper_limit="134.5"/>
                    <measurement group_id="O3" value="139.5" lower_limit="100.8" upper_limit="193.0"/>
                    <measurement group_id="O7" value="90.5" lower_limit="67.4" upper_limit="121.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 28 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="50.1" upper_limit="162.0"/>
                    <measurement group_id="O2" value="1011.6" lower_limit="509.5" upper_limit="2008.6"/>
                    <measurement group_id="O3" value="1229.9" lower_limit="586.5" upper_limit="2579.3"/>
                    <measurement group_id="O7" value="832.9" lower_limit="514.7" upper_limit="1347.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Neutralising Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>Antibody titers were expressed as GMTs.] Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Day 0 and Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Neutralising Antibody Titers Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>Antibody titers were expressed as GMTs.] Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0 (N=6;27;22;9;38;23;55;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.1" lower_limit="172.0" upper_limit="1021.2"/>
                    <measurement group_id="O2" value="254.8" lower_limit="184.0" upper_limit="352.8"/>
                    <measurement group_id="O3" value="221.2" lower_limit="145.0" upper_limit="337.6"/>
                    <measurement group_id="O4" value="292.0" lower_limit="170.8" upper_limit="499.1"/>
                    <measurement group_id="O5" value="441.3" lower_limit="317.5" upper_limit="613.5"/>
                    <measurement group_id="O6" value="212.8" lower_limit="142.3" upper_limit="318.1"/>
                    <measurement group_id="O7" value="254.2" lower_limit="200.2" upper_limit="322.9"/>
                    <measurement group_id="O8" value="329.3" lower_limit="260.0" upper_limit="417.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Month 6 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5080.1" lower_limit="2169.7" upper_limit="11894.4"/>
                    <measurement group_id="O2" value="2359.7" lower_limit="1852.0" upper_limit="3006.4"/>
                    <measurement group_id="O3" value="892.2" lower_limit="585.7" upper_limit="1359.0"/>
                    <measurement group_id="O4" value="292.6" lower_limit="173.6" upper_limit="493.0"/>
                    <measurement group_id="O5" value="528.9" lower_limit="377.5" upper_limit="741.0"/>
                    <measurement group_id="O6" value="221.6" lower_limit="155.0" upper_limit="316.8"/>
                    <measurement group_id="O7" value="1748.2" lower_limit="1347.3" upper_limit="2268.4"/>
                    <measurement group_id="O8" value="368.3" lower_limit="290.1" upper_limit="467.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0 (6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="7.2" upper_limit="64.0"/>
                    <measurement group_id="O2" value="20.7" lower_limit="13.9" upper_limit="30.7"/>
                    <measurement group_id="O3" value="26.1" lower_limit="16.8" upper_limit="40.6"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="22.7" lower_limit="17.4" upper_limit="29.7"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.5" lower_limit="89.4" upper_limit="905.6"/>
                    <measurement group_id="O2" value="140.0" lower_limit="81.7" upper_limit="240.0"/>
                    <measurement group_id="O3" value="113.1" lower_limit="58.2" upper_limit="219.7"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="138.9" lower_limit="95.2" upper_limit="202.6"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="13.6" upper_limit="85.3"/>
                    <measurement group_id="O2" value="78.4" lower_limit="47.0" upper_limit="131.1"/>
                    <measurement group_id="O3" value="136.5" lower_limit="97.4" upper_limit="191.3"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="89.2" lower_limit="65.5" upper_limit="121.5"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.1" lower_limit="136.0" upper_limit="512.9"/>
                    <measurement group_id="O2" value="618.2" lower_limit="435.1" upper_limit="878.5"/>
                    <measurement group_id="O3" value="638.2" lower_limit="381.1" upper_limit="1068.8"/>
                    <measurement group_id="O4" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="571.5" lower_limit="435.5" upper_limit="749.8"/>
                    <measurement group_id="O8" value="NA">Titers were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains</title>
        <description>Seropositivity was defined as antibody titers greater than or equal to 1:28.</description>
        <time_frame>Day 0 (for all groups) and Day 28 (for groups receiving Fluarix only)</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains</title>
          <description>Seropositivity was defined as antibody titers greater than or equal to 1:28.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Day 28 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0 (N=7;35;23;0;0;0;65;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 28 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0 (N=7;35;23;0;0;0;65;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O7" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day28 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>Seropositivity was defined as antibody titers greater than or equal to 1:28. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Day 0 and Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>Seropositivity was defined as antibody titers greater than or equal to 1:28. Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Day 0 (N=6;27;22;9;38;23;55;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="55"/>
                    <measurement group_id="O8" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Month 6 (N=6;28;22;9;38;23;56;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Day 0 (6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="52"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Day 0 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Month 6 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains in Subjects Receiving Fluarix</title>
        <description>Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Serum Neutralising Antibodies Against All Fluarix Vaccine Strains in Subjects Receiving Fluarix</title>
          <description>Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity at Day 28 which included all evaluable subjects for whom immunogenicity data at day 28 were available. Analysis was done only on those groups receiving the Fluarix vaccine.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (N=7;33;23;0;0;0;63;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (N=7;34;23;0;0;0;64;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O7" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
        <description>Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O7">
            <title>Fluarix All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine depending on their priming status.</description>
          </group>
          <group group_id="O8">
            <title>Havrix Junior All Ages Group</title>
            <description>Subjects aged 6 months to 9 years and previously vaccinated with Pandemrix vaccine, will receive two doses of Havrix Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Serum Neutralising Antibodies Against H1N1 in Subjects Receiving Havrix Junior Vaccine</title>
          <description>Seroconverted subject was a subject with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response.
Vaccine strains included in the analysis were H1N1, Victoria and H3N2 strains for subjects in groups receiving Fluarix vaccine and H1N1 strain for subjects in groups receiving Havrix Junior Vaccine.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence at Month 6 which included all evaluable subjects for whom immunogenicity data at Month 6 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (N=6;27;22;9;38;23;55;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (N=6;28;22;0;0;0;56;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O5" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O6" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="NA">Results were available only against H1N1 antigen in subjects receiving Havrix Junior Vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include: pain, redness and swelling. Any is any symptom regardless of intensity. Grade 3 was defined as a symptom that prevented normal activity.above 50 millimeter.</description>
        <time_frame>During the 7 days (Day 0 – 6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that had completed their symptom sheet for the respective vaccine dose only.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include: pain, redness and swelling. Any is any symptom regardless of intensity. Grade 3 was defined as a symptom that prevented normal activity.above 50 millimeter.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that had completed their symptom sheet for the respective vaccine dose only.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Any Solicited Local Symptom</title>
        <description>Duration was expressed as median number of days the symptom persisted. Solicited local symptoms assessed include: pain, redness and swelling.</description>
        <time_frame>During the 7 days (Days 0 – 6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that had completed their symptom sheet and reported the respective symptom only.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Any Solicited Local Symptom</title>
          <description>Duration was expressed as median number of days the symptom persisted. Solicited local symptoms assessed include: pain, redness and swelling.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects that had completed their symptom sheet and reported the respective symptom only.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain [Dose 1] (N= 3;23;20;5;19;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness [Dose 1] (N= 6;30;16;2;15;9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling [Dose 1] (N=5;18;9;1;10;5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain [Dose 2] (N= 2;21;14;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                    <measurement group_id="O6" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness [Dose 2] (N= 4;23;13;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                    <measurement group_id="O6" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling [Dose 2] (N=2;16;8;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                    <measurement group_id="O6" value="NA">None of the subjects from the Havrix Groups received a second vaccine dose within the frame of this study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Less Than 6 Years Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include diarrhoea, drowsiness, irritability, loss of appetite and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 loss of appetite was not eating at all; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the 7 days (Days 0–6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged less than 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Less Than 6 Years Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include diarrhoea, drowsiness, irritability, loss of appetite and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 loss of appetite was not eating at all; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged less than 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Any Solicited General Symptom Experienced by Subjects Less Than 6 Years Old</title>
        <description>Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include diarrhoea, drowsiness, irritability, loss of appetite and fever.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged less than 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Any Solicited General Symptom Experienced by Subjects Less Than 6 Years Old</title>
          <description>Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include diarrhoea, drowsiness, irritability, loss of appetite and fever.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged less than 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diarrhoea [Dose 1] (N=3;6;1;2;7;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness [Dose 1] (N=4;11;1;2;15;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability [Dose 1] (N=4;14;3;5;14;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite [Dose 1] (N=5;11;3;3;6;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever [Dose 1] (N=3;10;2;3;11;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea [Dose 2] (N=4;4;1;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness [Dose 2] (N=4;9;2;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability [Dose 2] (N=5;12;2;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="2.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite [Dose 2] (N=4;9;2;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever [Dose 2] (N=3;9;2;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                    <measurement group_id="O5" value="NA">None of the subjects in any of the Havrix Groups received a second vaccine dose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Above 6 Years Reported Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering, sweating and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged above 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Above 6 Years Reported Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering, sweating and fever. Any was defined as any symptom regardless of intensity; any fever was axillary temperature greater than or equal to 37.5 degrees celsius. Grade 3 was a symptom preventing normal everyday activity; grade 3 fever was axillary temperature above 39 degrees celsius. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged above 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gatrointestinal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gatrointestinal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gatrointestinal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Any Solicited General Symptom Experienced by Subjects Above 6 Years Old</title>
        <description>Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever.</description>
        <time_frame>During a 7-day follow-up period (Day 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged above 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Any Solicited General Symptom Experienced by Subjects Above 6 Years Old</title>
          <description>Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects aged above 6 years that had completed their symptom sheet for the respective vaccine dose only.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue [Dose 1] (N=0;0;4;0;0;8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue [Dose 2] (N=0;0;2;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O6" value="NA">Dose 2 involved subjects in Group receiving Fluarix vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Symptoms [Dose 1] (N=0;0;1;0;0;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms [Dose 2] (N=0;0;0;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">None of the subjects aged above 6 years in this group experienced this symptom</measurement>
                    <measurement group_id="O6" value="NA">Dose 2 involved subjects in Group receiving Fluarix vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache [Dose 1] (N=0;0;2;0;0;4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache [Dose 2] (N=0;0;2;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.5" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="NA">Dose 2 involved subjects in Group receiving Fluarix vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia [Dose 1] (N=0;0;0;0;0;2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">None of the subjects aged above 6 years in this group experienced this symptom.</measurement>
                    <measurement group_id="O6" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia [Dose 2] (N=0;0;1;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O6" value="NA">Dose 2 involved subjects in Group receiving Fluarix vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering [Dose 1] (N=0;0;2;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O6" value="NA">None of the subjects aged above 6 years in this group experienced this symptom.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering [Dose 2] (N=0;0;0;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">None of the subjects aged above 6 years in this group experienced this symptom</measurement>
                    <measurement group_id="O6" value="NA">Dose 2 involved subjects in Group receiving Fluarix vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever [Dose 1] (N=0;0;3;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O6" value="NA">None of the subjects aged above 6 years in this group experienced this symptom.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever [Dose2] (N=0;0;1;0;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O6" value="NA">Dose 2 involved subjects in Group receiving Fluarix vaccine.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as any symptom regardless of intensity or relationship to vaccination. Grade 3 was a symptom preventing normal everyday activity. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 28 day follow-up period (Day 0-27) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as any symptom regardless of intensity or relationship to vaccination. Grade 3 was a symptom preventing normal everyday activity. Related was any symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically-Attended Events (MAEs), Adverse Events of Specific Interest (AESIs)/ Potential Immune Mediated Diseases (pIMDs) and Adverse Events (AEs) of Special Interest</title>
        <description>MAEs: subject received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.
AESIs/pIMD: includes both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Adverse events of special interest include both convulsion and anaphylaxis.</description>
        <time_frame>During the entire study period (up to Month 6)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically-Attended Events (MAEs), Adverse Events of Specific Interest (AESIs)/ Potential Immune Mediated Diseases (pIMDs) and Adverse Events (AEs) of Special Interest</title>
          <description>MAEs: subject received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.
AESIs/pIMD: includes both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Adverse events of special interest include both convulsion and anaphylaxis.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESIs / pIMDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs of special interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to Month 6</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
          </group>
          <group group_id="O4">
            <title>Havrix Junior 6-11 Months Group</title>
            <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O5">
            <title>Havrix Junior 12-35 Months Group</title>
            <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Havrix Junior 3-9 Years Group</title>
            <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort which included all subjects with study vaccine administered.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed throughout the study period (from the beginning of the study up to Month 6). Systematically and non-systematically assessed frequent adverse events (AEs) were assessed during 7 days and 28 days post-vaccination.</time_frame>
      <desc>The following systematically assessed non-serious AEs were assessed only in subjects aged less than 6 years old: diarrhoea, drowsiness, irritability and loss of appetite. The following systematically assessed non-serious AEs were assessed only in subjects aged above 6 years old: fatigue, gastrointestinal symptoms, headache, myalgia and shivering.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluarix 6-11 Months Group</title>
          <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="E2">
          <title>Fluarix 12-35 Months Group</title>
          <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="E3">
          <title>Fluarix 3-9 Years Group</title>
          <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix™ vaccine depending on their priming status.</description>
        </group>
        <group group_id="E4">
          <title>Havrix Junior 6-11 Months Group</title>
          <description>Subjects aged 6 to 11 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
        <group group_id="E5">
          <title>Havrix Junior 12-35 Months Group</title>
          <description>Subjects aged 12 to 35 months and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
        <group group_id="E6">
          <title>Havrix Junior 3-9 Years Group</title>
          <description>Subjects aged 3 to 9 years and previously vaccinated with Pandemrix vaccine will receive two doses of Havrix™ Junior vaccine.</description>
        </group>
        <group group_id="E7">
          <title>Fluarix Group</title>
          <description>subjects received 1 or doses of Fluarix vaccine based on age and priming status</description>
        </group>
        <group group_id="E8">
          <title>Havrix Junior Group</title>
          <description>Subjects received 1 dose of Havrix Junior vacine. The second dose was administered outside the study setting.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lip haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tooth discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Loss of Appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>For subjects less than 6 years old</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>For subjects abvove 6 years old</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

